Exchange: NASDAQ·
News
all
press releases
ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 11%
Net product revenue in the fourth quarter surged 431% to $38.3 million, above estimates of $37.8 million, according to Fiscal.ai data
Stocktwits

Advertisement|Remove ads.